Abstract
Dysport (Clostridium botulinum type A toxin-haemagglutin complex) has had its licence extended to include treatment of children aged 2 years and over with dynamic equinus foot deformity, caused by spasticity associated with cerebral palsy. Dysport reduces muscle tone, thus improving function, relieving pain, and facilitating physiotherapy, application and tolerability of splints.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adolescent
-
Anti-Dyskinesia Agents / pharmacology*
-
Botulinum Toxins, Type A / therapeutic use*
-
Cerebral Palsy / drug therapy*
-
Cerebral Palsy / physiopathology
-
Child
-
Child, Preschool
-
Drug Combinations
-
Hemagglutinins / therapeutic use*
-
Humans
-
Infant
-
Muscle Spasticity / drug therapy
Substances
-
Anti-Dyskinesia Agents
-
Drug Combinations
-
Hemagglutinins
-
Botulinum Toxins, Type A